DE69535929D1 - Ligand (act-4-l) für einen rezeptor auf der oberfläche aktivierter cd4+ t - zellen - Google Patents

Ligand (act-4-l) für einen rezeptor auf der oberfläche aktivierter cd4+ t - zellen

Info

Publication number
DE69535929D1
DE69535929D1 DE69535929T DE69535929T DE69535929D1 DE 69535929 D1 DE69535929 D1 DE 69535929D1 DE 69535929 T DE69535929 T DE 69535929T DE 69535929 T DE69535929 T DE 69535929T DE 69535929 D1 DE69535929 D1 DE 69535929D1
Authority
DE
Germany
Prior art keywords
ligand
cells
activated
receptor
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535929T
Other languages
English (en)
Inventor
Wayne Godfrey
Edgar George Engleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R UNIVERSITY
Original Assignee
R UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22723580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69535929(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R UNIVERSITY filed Critical R UNIVERSITY
Application granted granted Critical
Publication of DE69535929D1 publication Critical patent/DE69535929D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69535929T 1994-02-10 1995-02-06 Ligand (act-4-l) für einen rezeptor auf der oberfläche aktivierter cd4+ t - zellen Expired - Lifetime DE69535929D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,967 US6242566B1 (en) 1994-02-10 1994-02-10 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
PCT/GB1995/000238 WO1995021915A1 (en) 1994-02-10 1995-02-06 Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells

Publications (1)

Publication Number Publication Date
DE69535929D1 true DE69535929D1 (de) 2009-04-23

Family

ID=22723580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535929T Expired - Lifetime DE69535929D1 (de) 1994-02-10 1995-02-06 Ligand (act-4-l) für einen rezeptor auf der oberfläche aktivierter cd4+ t - zellen

Country Status (12)

Country Link
US (10) US6242566B1 (de)
EP (1) EP0741784B1 (de)
JP (4) JP3703834B2 (de)
AT (1) ATE425252T1 (de)
AU (1) AU1583695A (de)
CA (1) CA2183066A1 (de)
DE (1) DE69535929D1 (de)
DK (1) DK0741784T3 (de)
ES (1) ES2323392T3 (de)
HK (1) HK1001462A1 (de)
PT (1) PT741784E (de)
WO (1) WO1995021915A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
WO1999042585A1 (en) † 1998-02-24 1999-08-26 Sisters Of Providence In Oregon Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US7622557B2 (en) * 1998-05-28 2009-11-24 St. Jude Children's Research Hospital Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP)
WO2001058953A2 (en) * 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
GB0123276D0 (en) * 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
CA2496795C (en) 2002-08-28 2014-06-03 Paul B. Burton Compositions and methods for treating cardiovascular disease
JP2006516094A (ja) * 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
MXPA05007019A (es) * 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20060280728A1 (en) * 2005-05-06 2006-12-14 Providence Health System Trimeric OX40-immunoglobulin fusion protein and methods of use
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AU2006343459A1 (en) 2005-12-16 2007-11-22 Genentech, Inc. Anti-OX40L antibodies and methods using same
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
PT2398498T (pt) * 2009-02-17 2018-12-03 Ucb Biopharma Sprl Moléculas de anticorpo tendo especificidade para ox40 humano
EP3309176A1 (de) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin variable einzeldomänen-antikörper gegen ox40l, konstrukte und therapeutische verwendung
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
US10696946B2 (en) * 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
KR101645112B1 (ko) 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
US10023626B2 (en) * 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
EP3126007B1 (de) 2014-04-03 2019-12-11 Augusta University Research Institute, Inc. Verfahren zur verbesserung der wirksamkeit einer tumor-gerichteten immunantwort
WO2015183902A1 (en) 2014-05-29 2015-12-03 Medimmune, Llc Ox40l fusion proteins and uses thereof
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
DK3209778T3 (da) 2014-10-24 2019-05-27 Astrazeneca Kombination
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
EP4137157A1 (de) 2015-03-03 2023-02-22 Kymab Limited Antikörper, verwendungen und verfahren
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
ES2936317T3 (es) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Anticuerpos contra OX40 y usos de los mismos
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
ES2969743T3 (es) 2015-09-10 2024-05-22 Becton Dickinson Co Análogos de la ciclofosfamida para uso como inmunógenos y conjugados en un inmunoensayo para la ciclofosfamida y la ifosfamida
JP6904947B2 (ja) * 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
EP3383430A4 (de) 2015-12-02 2019-12-18 Agenus Inc. Antikörper und verfahren zur verwendung davon
CA3025812A1 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
CA3075773A1 (en) 2017-09-21 2019-03-28 Becton, Dickinson And Company Hazardous contaminant collection kit and rapid testing
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3918300A4 (de) 2019-01-28 2022-11-16 Becton, Dickinson and Company Schadstoffsammelvorrichtung mit integriertem tupfer und testvorrichtung
WO2021064567A1 (en) 2019-09-30 2021-04-08 Astrazeneca Ab Combination treatment for cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51146432A (en) * 1975-06-12 1976-12-16 Microbial Chem Res Found Process for preparation of benzanilide derivatives having therapeutic action to immunological disease
ES2095876T3 (es) 1989-06-02 1997-03-01 Univ Johns Hopkins Med Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
WO1992011870A1 (en) 1991-01-11 1992-07-23 Repligen Corporation Method of preventing inflammatory damage
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
WO1995021915A1 (en) 1995-08-17
PT741784E (pt) 2009-06-18
JP2006254914A (ja) 2006-09-28
EP0741784A1 (de) 1996-11-13
HK1001462A1 (en) 1998-06-19
JP3703834B2 (ja) 2005-10-05
US20070092511A1 (en) 2007-04-26
US6528055B2 (en) 2003-03-04
AU1583695A (en) 1995-08-29
JP4109263B2 (ja) 2008-07-02
JP4745872B2 (ja) 2011-08-10
US20090069535A1 (en) 2009-03-12
ES2323392T3 (es) 2009-07-14
JP2010046060A (ja) 2010-03-04
JPH09509826A (ja) 1997-10-07
US20020077460A1 (en) 2002-06-20
US20100240873A1 (en) 2010-09-23
US20040006207A1 (en) 2004-01-08
JP2005245448A (ja) 2005-09-15
US7125670B2 (en) 2006-10-24
US7098184B2 (en) 2006-08-29
US20060217531A1 (en) 2006-09-28
US20010044523A1 (en) 2001-11-22
DK0741784T3 (da) 2009-06-22
CA2183066A1 (en) 1995-08-17
US20030149247A1 (en) 2003-08-07
ATE425252T1 (de) 2009-03-15
US6528623B2 (en) 2003-03-04
US6156878A (en) 2000-12-05
US6242566B1 (en) 2001-06-05
EP0741784B1 (de) 2009-03-11

Similar Documents

Publication Publication Date Title
ATE425252T1 (de) Ligand (act-4-l) für einen rezeptor auf der oberfläche aktivierter cd4+ t - zellen
Vánky et al. Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor.
ATE454449T1 (de) Menschlicher rezeptor h4-1bb
BG99605A (en) Antagonists of the growth factor or endothelial cells of the circulatory system
BG102265A (en) Soluble receptors for lymphotoxin-beta and antibodies against the receptor for lymphotoxin and its ligand as therapuetical substances for the threatment of immunological diseases
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE166387T1 (de) Adhäsionsvarianten
ATE195149T1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
ATE132197T1 (de) Monoklonale antikörper
DK0489837T4 (da) Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
EP0674661A4 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis.
DE69736244D1 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
DE69535501D1 (de) Identifikation, reinigung und verwendungen von leczymen und karbohydratliganden
DE69314024D1 (de) NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE
Aiello et al. A role for cytokines in antigen presentation: IL-1 and IL-4 induce accessory functions of antigen-presenting cells.
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
Górski et al. Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactions
DE3855236D1 (de) Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
ATE173503T1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
DE3850750D1 (de) Verfahren zur Verhütung von GVHD.
ATE237139T1 (de) Verfahren zur identifizierung personen empfindlich für betahemolytischer streptococci- vermittelter neuropsychiatrischer krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition